ICDs Are Primary Defense Against Sudden Cardiac Death

82 views
49 views

Published on

The review showed that the number of patients needed to treat to prevent one death ranged from 6.2 to 22 after 3 to 7 years of follow-up.

Published in: Health & Medicine
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
82
On SlideShare
0
From Embeds
0
Number of Embeds
2
Actions
Shares
0
Downloads
1
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

ICDs Are Primary Defense Against Sudden Cardiac Death

  1. 1. News From: For Immediate Release Contact: Damian Becker, Manager of Media Relations (516) 377-5370 October 24, 2013 ICDs Are Primary Defense Against Sudden Cardiac Death Photo Caption (KannerwRevo): Dr. Lawrence Kanner, FACC, director of Electrophysiology and Arrhythmia Services at South Nassau, displays a model of the Revo MRI™ SureScan® pacing system, the first pacemaker in the U.S. specifically designed for use in a MRI environment. Photo Caption (BioEvia2): The Evia® pacemaker incorporates a wireless monitoring system that immediately notifies the patient’s physician if the patient or the pacemaker is experiencing complications. Oceanside, NY – A literature review by the Agency for Healthcare Research and Quality (AHRQ) strongly supports the use of implantable cardioverter defibrillators (ICDs) as primary prevention of sudden cardiac death (SCD) over non-ICD therapy. The review is based on the outcomes of seven randomized, controlled trials that showed a "high strength of evidence" that ICD reduces all-cause mortality and SCD. The review is meant to be used by health plans, patients, providers, and purchasers to develop clinical practice guidelines and other quality enhancement tools. "What the AHRQ review proves is that ICDs are an effective, patient-centered therapy to prevent sudden cardiac death (SCD) and for treating heart failure, while reducing unnecessary hospitalizations," said Lawrence Kanner, MD, FACC, director of Electrophysiology and Arrhythmia Services at South Nassau. The review showed that the number of patients needed to treat to prevent one death ranged from 6.2 to 22 after 3 to 7 years of follow-up. It also reported that in-hospital adverse events caused by ICDs were infrequent (1-3%) and 20% of patients receive an inappropriate shock in 1 to 5 years of follow-up. Each year, SCD claims the lives of up to 460,000 people in the U.S. alone, and more people die from SCD than from lung cancer, breast cancer and AIDS combined. Nearly 22 million people worldwide currently suffer from heart failure, a debilitating condition in which
  2. 2. the heart weakens and gradually loses the ability to pump blood effectively. Approximately one million new cases of heart failure are diagnosed annually worldwide, making it the most rapidly growing cardiovascular disorder. Dr. Kanner and South Nassau’s Center for Cardiovascular Health have been in the forefront in providing heart failure patients on Long Island with the latest advancements in ICD devices and electrophysiology services. Dr. Kanner was the first on Long Island to implant the Viva® cardiac resynchronization therapy with defibrillation (CRT-D); Incepta® ICD (recognized as the world’s smallest and thinnest ICD); Evia® pacemaker (which incorporates wireless monitoring system that immediately notifies the patient’s physician if the patient or the pacemaker is experiencing complications) and Revo MRI™ SureScan® pacing system (the first pacemaker in the U.S. specifically designed for use in a MRI environment). In addition to ICDs, Dr. Kanner and electrophysiologists at South Nassau’s Center for Cardiovascular Health use an array of advanced technologies to provide timely, accurate diagnoses and therapies to treat the range of cardiac arrhythmias (abnormal heart rhythms) and defibrillator maintenance. Services include diagnostic studies, implantation and testing of pacemakers, and radiofrequency catheter ablation for the treatment of potentially fatal irregular heartbeats. South Nassau Communities Hospital is a recipient of the American College of Cardiology (ACC) Foundation’s National Cardiology Data Registry (NCDR) ACTION Registry–Get With the Guidelines (GWTG) Silver Performance Achievement Award. The GWTG program is a quality-improvement program that helps hospitals provide cardiac and stroke care in accordance with the most up-to-date guidelines and recommendations. Hospitals that continually meet or exceed the nationally accepted standards, or guidelines, improve their quality patient care by turning guidelines into “lifelines”. Upon meeting specific criteria, hospitals are recognized for performance achievement if at least 85 percent of their cardiac or stroke patients are treated and discharged according to the American Heart Association/American Stroke Association’s guidelines and recommendations. South Nassau Communities Hospital is one of the region’s largest hospitals, with 435 beds, more than 900 physicians and 3,000 employees. Located in Oceanside, NY, the hospital is an acute-care, not-for-profit teaching hospital that provides state-of-the-art care in cardiac, oncologic, orthopedic, bariatric, pain management, mental health and emergency services. In addition to its extensive outpatient specialty centers, South Nassau provides emergency and elective angioplasty and is the only hospital on Long Island with the Novalis Tx™ and Gamma Knife® Perfexion radiosurgery technologies. South Nassau is a designated Stroke Center by the
  3. 3. New York State Department of Health and Comprehensive Community Cancer Center by the American College of Surgeons and is recognized as a Bariatric Surgery Center of Excellence by the American Society for Metabolic and Bariatric Surgery. For more information, visit www.southnassau.org. -30-

×